Clinical Trial

Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: a Comparative Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2024 (before its estimated July 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient. Advances in cell biotechnology, particularly fibroblast therapy, show promise for enhancing wound healing, as fibroblasts play a crucial role in tissue repair and inflammation. This study aims to develop, assess, and evaluate the safety of a combined treatment approach that incorporates fibroblast therapy with existing methods for managing chronic non-healing wounds in PAD patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-04.
Trial Details
NCT Number NCT06724276
Lead Sponsor Tulip Medicine
Collaborators: National Research Oncology and Transplantology Center, Kazakhstan
Conditions Obliterans, Arteriosclerosis, Peripheral Arterial Disease, Diabetic Foot
Enrollment 116 participants
Start Date 2023-01-09
Primary Completion 2025-07-10 (estimated)
Study Completion 2025-09-06 (estimated)
Updated on ClinicalTrials.gov 2024-12-12